Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LESS: De-escalating Adjuvant Endocrine Therapy in Very Low Risk Breast Cancer
NCT05297617Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Oct 2022
- Primary completion
- Nov 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, sponsored by Unicancer. Primary endpoint: Distant relapse-free interval at 5 years. Started Oct 2022; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05297617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297617.